Registration form - 2013

Registration form - 2013 tài liệu, giáo án, bài giảng , luận văn, luận án, đồ án, bài tập lớn về tất cả các lĩnh vực kin...

KRONE Premis NET ® SYSTEM WARRANTY CONDITIONS FOR END USER The Premis NET System Warranty is subject to the following conditions. ENDORSED INSTALLER COMPANIES and END USERS should both read these carefully. If you are in any doubt as to their meaning please contact the Warranty Co-ordinator at KRONE in writing before completing the WARRANTY REGISTRATION FORM. It is a condition that the installation instruction sheets and other written instructions have been adhered to during installation. ENDORSED INSTALLER COMPANIES should contact KRONE where there is any difficulty with your understanding of these. 1. DEFINITIONS 1.1 In these conditions: END USER The company to whom the System Warranty Certificate has been issued. KRONE KRONE (Australia) Holdings Pty Limited 2 Hereford Street Berkeley Vale NSW 2261 Australia ENDORSED Means a company authorised in INSTALLER writing by KRONE to be an COMPANY ENDORSED INSTALLER COMPANY, and to design and install a SYSTEM to which the warranties herein shall apply whereby such design and installation is conducted by its staff who are trained and certified to be thus trained by KRONE. PRODUCTS Means those KRONE PRODUCTS listed in the KRONE WARRANTY REGISTRATION FORM. WARRANTY Means the form used to apply for REGISTRATION the warranties herein. FORM APPLICABLE Means the published cabling STRUCTURED standard(s) referred to in sub-section CABLING “Compliance” of the KRONE STANDARDS WARRANTY Registration Form current at the date of registration. SPECIFICATIONS Means the performance requirements defined in the Applicable Structured Cabling Standards and such other performance requirements as are specified in writing by KRONE and to which the System has been tested. SYSTEM Means any combination of the three sub-systems of a structured CABLING SYSTEM as defined in the APPLICABLE STRUCTURED CABLING STANDARDS (campus, backbone, horizontal) and such variations thereto as are specified in writing by KRONE, and which are composed of the Products. WARRANTY Means up to 20 years from the date PERIOD of completion of installation of the SYSTEM. 1.2 Headings are included for ease of reference only and shall not affect the interpretation of these conditions. 2. PREMIS NET SYSTEM WARRANTY 2.1 KRONE warrants to the END USER that the tested SYSTEM in its installed state shall meet or exceed the SPECIFICATIONS in force at the time of installation for the duration of the WARRANTY PERIOD. 2.2 KRONE warrants to the END USER that the Products which comprise the SYSTEM shall be free from defects in materials and workmanship for the duration of the WARRANTY PERIOD. 3. APPLICATIONS ASSURANCE WARRANTY 3.1 KRONE warrants to the END USER that, for the duration of the WARRANTY PERIOD, the system shall be free from defects which prevent operation of: 3.1.1 applications specified by recognised standards or user forums that use the APPLICABLE STRUCTURED CABLING STANDARDS, and 3.1.2 any other applications specified in writing by KRONE. 4. ZERO BIT ERROR WARRANTY 4.1 KRONE warrants that the horizontal sub systems of a GLOBAL LEADER SYSTEM shall have a “Zero Bit Error” rate of no greater than 10-12 for a period of five (5) years from the date of installation. 5. ENTERPRISE WARRANTY 5.1 The ENTERPRISE SYSTEM provides all the warranty assurances detailed above in Clause 2 – Premis NET System Warranty and Clause 3 – Applications Assurance Warranty. 6. GLOBAL LEADER WARRANTY 6.1 The GLOBAL LEADER Warranty comprises all the warranties detailed in Clause 2 – Premis NET SYSTEM WARRANTY; Clause 3 – Applications Assurance Warranty and Clause 4 – Zero “ HOLCIM PRIZE – 2013 ” PHIẾU ĐĂNG KÝ ĐỀ TÀI Họ tên người đăng ký: Trường: Khoa: Số điện thoại: Email: MSSV: Lĩnh vực đề tài : Phát Triển Cộng Đồng (CD – Community Development) Bảo vệ Môi trường (SEP – Sustainable Environment Performance) Xây dựng Bền vững (SC – Sustainable Construction) Tên đề tài đăng ký : Người thực đề tài : Cá nhân Nhóm Thông tin cá nhân thành viên: HỌ VÀ TÊN Số điện thoại Email Người hướng dẫn: Email: Số điện thoại: Sinh viên gửi phiếu đăng ký liên lạc: (e-file): vnm@holcim.com 08 – 3.914.9000 holcimprizeExt : 1033 Tp.Hồ Chí Minh, ngày…tháng…năm 20 Người đăng ký Ghi : Phiếu đăng ký tham dự nộp hạn chót 21/12/2012  Waiver of Business Registration Fees for One Year (from 1 April 2012 to 31 March 2013) 1. The Revenue (Reduction of Business Registration Fees) Order 2012 (“the Order”) comes into effect on 1 April 2012. 2. By the Order, the fees payable under section 5A(1)(a) in respect of local companies registered under the One-stop company incorporation and business registration regime (“One-stop Registration”) will be reduced by a sum of $2,000 if the related incorporation applications are made within the period from 1 April 2012 to 31 March 2013 (“Waiver Period”). For other cases, the fees payable in respect of business registration certificates and branch registration certificates with commencement date falling within the Waiver Period will be reduced by a sum of $2,000 and $73 respectively. 3. Businesses are still required to pay the levy for the Protection of Wages on Insolvency Fund. 4. Please refer to the business registration fee & levy table for details of the total amount payable in respect of a registration certificate. 5. The Business Registration Office has not demanded and will not demand businesses or branches the registration fees for the Waiver Period in the renewal demand notes in respect of certificates with commencement date falling within the Waiver Period. Hence, those who receive demand notes from the Business Registration Office have to settle the amounts demanded thereon when due. Concessionary Refund of Registration Fees Paid 6. The Order only applies to incorporation applications made under the One-stop Registration within the Waiver Period or, in other cases, new certificates or renewal certificates with commencement date falling within the Waiver Period. It does not provide for the refund of registration fees paid in respect of the Waiver Period. 7. In order that the waiver can also benefit those businesses that have paid the business registration fees or branch registration fees for the Waiver Period but are not required to renew their certificates in such period, concessionary refunds of 1 the relevant amount of registration fees paid will be allowed to them, upon applications (see paragraph 13 below). Who is eligible 8. The following types of businesses:- (a) Businesses or branches, which hold a 3-year registration certificate with a commencement date before 1 April 2012 and an expiry date on or after 31 March 2013; (b) Ceased businesses or branches, which last hold a 1-year registration certificate with a commencement date between 1 August 2011 and 31 March 2012; (c) Ceased businesses or branches, which last hold a 3-year registration certificate with an expiry date between 1 April 2012 and 31 March 2013; and (d) Local companies registered under the One-stop Registration, which make incorporation applications between 1 August 2011 and 31 March 2012 and hold a 1-year or 3-year business registration certificate with a commencement date between 1 April 2012 and 31 March 2013. How to apply 9. Based on the information in its database, the Business Registration Office will start issuing invitation letter and the application form IRBR188(2/2012) from Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents Recommendations for HIV-prevalent and resource-constrained settings Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents Recommendations for HIV-prevalent and resource-constrained settings STOP TB DEPARTMENT DEPARTMENT OF HIV/AIDS © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publica- tion. However, the published material is being distributed without warranty of any kind, either expressed or implied. The respon- sibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. The named authors alone are responsible for the views expressed in this publication. Contents Acknowledgements iv Abbreviations v Part I. Improving the diagnosis and treatment of smear-negative tuberculosis 1 Background 3 Target audience 3 Process of formulation 3 Strength of the recommendations 4 Implementation and evaluation 4 Recommendations 5 Algorithms for the diagnosis of smear-negative tuberculosis 8 Part II. Simplified and standardized clinical management guidelines for extrapulmonary tuberculosis 15 Background 17 Target audience 17 Diagnosis and management 17 Further reading 23 References 24 Annex. Protocol for operational evaluation of the revised recommendations and algorithms for improving the diagnosis of tuberculosis in HIV-prevalent settings 27 Background 29 Objectives of the evaluation 29 Purpose of the protocol 29 Hypotheses 30 Study design and procedure 30 References 36 iii Prepared by Members of the WHO Expert Group on Smear- Negative TB: Getachew Aderaye (Addis Ababa University, Ethiopia), Ludwig Apers (Institute of Tropical Medicine, Antwerp, Belgium), Leopold Blanc (World Health Organization, M I N D S & H E A R T S: A Specialist Clinic for Autism Spectrum Conditions Autism Spectrum Conditions: Diagnosis and Treatment, Advanced Workshop – Melbourne, VIC, Australia Thursday 25th & Friday 26th July 2013, 9.00am – 4.30pm Presented by: Professor Tony Attwood & Dr Michelle Garnett Professor Tony Attwood is a world expert and leading authority on Asperger’s Syndrome (AS) and autism Tony is a clinical psychologist who has specialised in Introduction  Humanimmunodeciencyvirus(HIV)associated tuberculosis(TB)remainsamajorglobalpublichealth challenge. By the end of 2009, an estimated 33.3 millionpeoplewerelivingwithHIV,thevastmajority in sub-Saharan Africa and Asia. An estimated 2.6 million individuals had become newly infected with HIV and 1.8 million had died of AIDS in that year alone 1 .TBisthemostcommonopportunisticinfection (OI)amongHIV-infectedindividuals,andco-infected individuals are at high risk of death 2,3 .Theestimates oftheglobalburdenofdiseasecausedbyTBin2009 Review Article Diagnosis&treatmentoftuberculosisinHIVco-infectedpatients C.Padmapriyadarsini,G.Narendran&SoumyaSwaminathan National Institute for Research in Tuberculosis (Indian Council of Medical Research), Chennai, India ReceivedOctober31,2011 Human immunodeciency virus (HIV) associated tuberculosis (TB) remains a major global public health challenge, with an estimated 1.4 million patients worldwide. Co-infection with HIV leads to challenges in both the diagnosis and treatment of tuberculosis. Further, there has been an increase in rates of drug resistant tuberculosis, including multi-drug (MDR-TB) and extensively drug resistant TB (XDRTB), which are difcult to treat and contribute to increased mortality. Because of the poor performance of sputum smear microscopy in HIV-infected patients, newer diagnostic tests are urgently required that are not only sensitive and specic but easy to use in remote and resource-constrained settings. The treatment of co-infected patients requires antituberculosis and antiretroviral drugs to be administered concomitantly; challenges include pill burden and patient compliance, drug interactions, overlapping toxic effects, and immune reconstitution inammatory syndrome. Also important questions about the duration and schedule of anti-TB drug regimens and timing of antiretroviral therapy remain unanswered. From a programmatic point of view, screening of all HIV-infected persons for TB and vice- versa requires good co-ordination and communication between the TB and AIDS control programmes. Linkage of co-infected patients to antiretroviral treatment centres is critical if early mortality is to be prevented. We present here an overview of existing diagnostic strategies, new tests in the pipeline and recommendations for treatment of patients with HIV-TB dual infection. Key words Co-infection-diagnosis-drugresistance-HIV-IRIS-treatment-tuberculosis wereasfollows:9.4millionincidentcases(range8.9- 9.9 million), 1.3million deaths amongHIV-negative TB patients (range 1.2-1.5 million) and 0.38 million deaths among HIV-positiveTB patients (range 0.32- 0.45million).MostTBcaseswereintheSouth-East Asia, African and Western Pacic regions (35, 30 and 20%, respectively).Anestimated 11-13 per cent of incident cases were HIV-positive 4 . TB may occur atanystageofHIVdiseaseandisfrequentlytherst recognizedpresentationofunderlyingHIVinfection 5,6 . AscomparedtopeoplewithoutHIV,peoplelivingwith HIV(PLWH)havea20-foldhigherriskofdeveloping 850 IndianJMedRes134,December2011,pp850-865 TB 7  and the risk continues to increase as CD4 cell countsprogressivelydecline 5 .  AsaresultofWHO’s3by5campaign,>6million HIV-infected individuals in resource limited settings havehadaccesstoantiretroviraltherapy(ART)since 2004 8 ,thoughthisisstillfarshortoftheactualneed. AlthoughART can reduce the incidence of TB both at the individual and population level, M I N D S & H E A R T S: A Specialist Clinic for Autism Spectrum Conditions Autism Spectrum Conditions: Diagnosis and Treatment, Basic Workshop – Melbourne, VIC, Australia Int. J. Med. Sci. 2010, 7 http://www.medsci.org 72IInntteerrnnaattiioonnaall JJoouurrnnaall ooff MMeeddiiccaall SScciieenncceess 2010; 7(2):72-81 © Ivyspring International Publisher. All rights reserved Research Paper WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE Miwako Narita1 , Masayoshi Masuko2, Tohri Kurasaki3, Toshiki Kitajima3, Shoko Takenouchi3, Anri Sai-toh1, Norihiro Watanabe1, Tatsuo Furukawa2, Ken Toba3, Ichiro Fuse4, Yoshifusa Aizawa3, Manabu Kawa-kami5, Yoshihiro Oka6, Haruo Sugiyama6 and Masuhiro Takahashi1 1. Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, Niigata, Japan 2. Division of Stem Cell Transplantation, Niigata University Medical and Dental General Hospital, Niigata, Japan 3. Division of Hematology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan 4. Division of Bioscience Medical Research Center, Niigata University Medical and Dental General Hospital, Niigata, Japan 5. Department of Medicine, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan 6. Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka, Japan  Corresponding author: Miwako Narita M.D., Laboratory of Hematology and Oncology, Graduate School of Health Sciences, Niigata University, 2-746, Asahimachi-dori, Chuo-ku, Niigata, 951-8518 Japan. (Telephone/fax) 81-25227-0836, (email) naritami@clg.niigata-u.ac.jp Received: 2009.11.07; Accepted: 2010.04.09; Published: 2010.04.20 Abstract Although tyrosine kinase inhibitors is effective for dramatically reducing CML cells, it might be difficult to eradicate completely the CML stem cells. We aimed to clarify the safety and effects of WT1 peptide vaccination in combination with imatinib therapy for a CML patient. A 51 year-old male with CML in CP, who showed a resistance against imatinib therapy for 2.5 years, began to be treated with 9mer modified-type WT1 peptides in combination with standard dose of imatinib. Although every 2-week-administration of WT1 peptides for 22 weeks did not show definite effects on the quantification of bcr-abl transcripts, by changing the admin-istration from every 2 weeks to 4 weeks bcr-abl transcripts decreased remarkably. After 11 months of every 4-week-administration of the peptides and 12 months post cessation of the peptides bcr-abl transcripts achieved to the level below detection by RQ/RT-PCR (complete molecular response). WT1/MHC tetramer+CD8+ CTLs, which appeared after the second administration of WT1 peptides and remained more than 15 in number among 106 CD8+ T cells throughout the administration of WT1 peptides, are still present in the blood on 14th month post cessation of the peptides. An in vitro study as to the cytotoxicity of lymphocytes induced by mixed lymphocyte peptide culture demonstrated that cultured lymphocytes possessed cytotoxicity against WT1 expressing leukemia cells and the cytotoxicity was WT1-specific and MHC class I restricted. The present study showed that WT1 peptide vaccination in combination with TKI is feasible and effective in the therapy for imati-nib-resistant CML. Key words: WT1 peptide vaccination, CML, imatinib, bcr-abl transcripts, WT1 tetramer, cytotoxic-ity INTRODUCTION While tyrosine kinase inhibitors (TKIs) such as imatinib are currently regarded as M I N D S & H E A R T S: Working with the Mind through the Heart Succeeding with Asperger’s Syndrome in the Teens Melbourne, VIC, Australia Saturday 16th March 2013, 9.30am – 4.00pm Prof Tony Attwood & Dr Michelle Garnett Professor Tony Attwood is a world